KWANGDONG PHARMACEUTICAL (009290) Financial Statements

OverviewFinancialsChecksFilings

In fiscal year 2025, KWANGDONG PHARMACEUTICAL (009290) reported revenue of 1.66 trillion KRW.

Income Statement

YearRevenueOp ProfitNet IncomeSource
20251.66 trillion KRW31.0 billion KRW21.3 billion KRW[source]
20241.64 trillion KRW30.1 billion KRW41.8 billion KRW[source]
20231.51 trillion KRW42.1 billion KRW39.4 billion KRW[source]
20221.43 trillion KRW38.2 billion KRW26.7 billion KRW[source]
20211.34 trillion KRW44.9 billion KRW25.5 billion KRW[source]

Balance Sheet

YearTotal AssetsTotal LiabilitiesTotal EquitySource
20251.02 trillion KRW408.9 billion KRW613.8 billion KRW[source]
2024932.4 billion KRW390.4 billion KRW541.9 billion KRW[source]
2023855.3 billion KRW329.5 billion KRW525.8 billion KRW[source]
2022767.6 billion KRW261.6 billion KRW506.0 billion KRW[source]
2021716.9 billion KRW231.2 billion KRW485.8 billion KRW[source]

Cash Flow

YearOperatingInvestingFinancingSource
202582.3 billion KRW-102.6 billion KRW45.5 billion KRW[source]
2024-12.2 billion KRW12.8 billion KRW36.8 billion KRW[source]
2023-11.7 billion KRW-71.8 billion KRW58.0 billion KRW[source]
202262.8 billion KRW-42.7 billion KRW-628 million KRW[source]
202154.9 billion KRW-43.0 billion KRW15.9 billion KRW[source]
Financials & Filings: DART (traceable by receipt number) · Prices: Financial Services Commission · Data Sources · Last checked: 2026-08-30 · About · Delisting market cap threshold: KOSPI 5B KRW / KOSDAQ 4B KRW (per listing rules) · EPS, DPS, and dividend yield are DART disclosure values. PER is calculated as closing price / disclosed EPS · This page provides factual information, not investment advice